文献速递核素与放射性配体治疗肿瘤 PET/CT

[68Ga]Ga-DOTA-TATE摄取与[177Lu]Lu-DOTA-TATE治疗中吸收剂量的关系

Relationships between uptake of [68Ga]Ga-DOTA-TATE and absorbed dose in [177Lu]Lu-DOTA-TATE therapy.
PubMed 文献 · EJNMMI Res · 2022-12-19

该研究纳入18例神经内分泌肿瘤患者,在首次[177Lu]Lu-DOTA-TATE治疗前20周内行[68Ga]Ga-DOTA-TATE PET显像,用混合SPECT/CT-平面法估算肿瘤、肾、脾及正常肝实质的吸收剂量。结果显示,在组水平上[68Ga]Ga-DOTA-TATE高摄取与[177Lu]Lu-DOTA-TATE治疗高吸收剂量相关,但该关系对个体化吸收剂量规划的潜力有限。

要点

  • 正常器官中仅脾显示[68Ga]活性浓度与[177Lu]吸收剂量显著相关(r=0.6)。
  • 肿瘤的组间相关系数r=0.7、组内r=0.45,使用SUV或归一化SUV未改善相关性。
  • 肿瘤[177Lu]吸收剂量可由[68Ga]活性浓度预测,95%覆盖区间为-65%至248%。

核心结论

  • 在组水平上,[68Ga]Ga-DOTA-TATE高摄取与[177Lu]Lu-DOTA-TATE治疗高吸收剂量相关,但该关系对个体化吸收剂量规划的潜力有限。
  • 使用SUV或经参考组织归一化的SUV,与使用每注射活度的活性浓度相比,未改善相关性。

研究设计与样本

  • 18例患者在其首周期[177Lu]Lu-DOTA-TATE治疗前20周内接受[68Ga]Ga-DOTA-TATE PET显像。
  • 采用混合SPECT/CT-平面法估算肿瘤、肾、脾和正常肝实质的治疗吸收剂量。
  • 从PET图像获取镓-68活性浓度,并计算SUV及以血液和组织归一化的SUV。
  • 将每注射活度的镓-68活性浓度、SUV和归一化SUV与注射后1天的镥-177活性浓度及镥-177吸收剂量进行比较。
  • 肿瘤每例数量可变,分析组间和组内相关性,并探索基于肿瘤特异性镓-68活性浓度联合1级和2级神经内分泌肿瘤群体有效半衰期估算来预测镥-177肿瘤吸收剂量。

主要发现

  • 正常器官中仅脾显示镓-68活性浓度与镥-177吸收剂量显著相关(r=0.6)。
  • 肿瘤相关性显著但中等,组间分析r=0.7,组内分析r=0.45。
  • 使用镓-68 SUV或归一化SUV未改善与吸收剂量的相关性。
  • 镓-68 PET与镥-177 SPECT活性摄取之间的关系更强,组间和组内分析的相关系数均为r=0.8。
  • 肿瘤镥-177吸收剂量可由镓-68活性浓度预测,95%覆盖区间为-65%至248%。

关键数值与推荐

  • 脾:镓-68活性浓度与镥-177吸收剂量相关r=0.6(显著)。
  • 肿瘤组间分析:与镥-177吸收剂量相关r=0.7(显著但中等)。
  • 肿瘤组内分析:与镥-177吸收剂量相关r=0.45(显著但中等)。
  • 镓-68 PET与镥-177 SPECT活性摄取相关:组间和组内分析r均为0.8。
  • 肿瘤镥-177吸收剂量预测的95%覆盖区间为-65%至248%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Somatostatin receptor 68Ga PET imaging is standard for evaluation of a patient's suitability for 177Lu peptide receptor radionuclide therapy of neuroendocrine tumours (NETs). The 68Ga PET serves to ensure sufficient somatostatin receptor expression, commonly evaluated qualitatively. The aim of this study is to investigate the quantitative relationships between uptake in 68Ga PET and absorbed doses in 177Lu therapy. METHOD: Eighteen patients underwent [68Ga]Ga-DOTA-TATE PET imaging within 20 weeks prior to their first cycle of [177Lu]Lu-DOTA-TATE. Absorbed doses for therapy were estimated for tumours, kidney, spleen, and normal liver parenchyma using a hybrid SPECT/CT-planar method. Gallium-68 activity concentrations were retrieved from PET images and also used to calculate SUVs and normalized SUVs, using blood and tissue for normalization. The 68Ga activity concentrations per injected activity, SUVs, and normalized SUVs were compared with 177Lu activity concentrations 1 d post-injection and 177Lu absorbed doses. For tumours, for which there was a variable number per patient, both inter- and intra-patient correlations were analysed. Furthermore, the prediction of 177Lu tumour absorbed doses based on a combination of tumour-specific 68Ga activity concentrations and group-based estimates of the effective half-lives for grade 1 and 2 NETs was explored. RESULTS: For normal organs, only spleen showed a significant correlation between the 68Ga activity concentration and 177Lu absorbed dose (r = 0.6). For tumours, significant, but moderate, correlations were obtained, with respect to both inter-patient (r = 0.7) and intra-patient (r = 0.45) analyses. The correlations to absorbed doses did not improve when using 68Ga SUVs or normalized SUVs. The relationship between activity uptakes for 68Ga PET and 177Lu SPECT was stronger, with correlation coefficients r = 0.8 for both inter- and intra-patient analyses. The 177Lu absorbed dose to tumour could be predicted from the 68Ga activity concentrations with a 95% coverage interval of - 65% to 248%. CONCLUSIONS: On a group level, a high uptake of [68Ga]Ga-DOTA-TATE is associated with high absorbed doses at 177Lu-DOTA-TATE therapy, but the relationship has a limited potential with respect to individual absorbed dose planning. Using SUV or SUV normalized to reference tissues do not improve correlations compared with using activity concentration per injected activity.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Stenvall A, Gustafsson J, Larsson E, et al. Relationships between uptake of [68Ga]Ga-DOTA-TATE and absorbed dose in [177Lu]Lu-DOTA-TATE therapy. EJNMMI Res. 2022. PMID: 36534192. doi:10.1186/s13550-022-00947-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。